Literature DB >> 20946109

Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

A Packeu1, M Wennerberg, A Balendran, G Vauquelin.   

Abstract

BACKGROUND AND
PURPOSE: Because the in vivo effectiveness of ligands may also be determined by the rate by which they dissociate from their target receptors, drug candidates are being increasingly screened for this kinetic property. The dissociation rate of unlabelled ligand-receptor complexes can be estimated indirectly from their ability to slow the association of subsequently added radioligand molecules. EXPERIMENTAL APPROACH: We used the 'two-step competition' binding approach consisting of pre-incubating the receptor preparation with a wide range of ligand concentrations, washing off free ligand molecules, adding radioligand and monitoring its receptor binding after a fixed time. Based on the rationale that binding of both ligands is mutually exclusive and that they bind according to the law of mass action to a single class of sites, the unlabelled ligand's dissociation rate can be estimated from the upward shift that the competition curve experiences after washing. KEY
RESULTS: The relevance of the 'two-step competition' approach was explored by computer simulations and by comparing the dissociation behaviour of unlabelled D(2) dopamine and CB(1) cannabinoid receptor antagonists in this and alternative approaches. Besides providing satisfactory estimations of dissociation rates, the method also detects the ability of the unlabelled ligand molecules to be released from 'sinks' such as the cell membrane. CONCLUSIONS AND IMPLICATIONS: As the 'two-step competition' requires rapid intermediate washing steps and needs radioligand binding to be measured at only one time point, this approach is particularly suited for binding studies on intact plated cells. LINKED ARTICLES: This article is part of a themed section on Analytical Receptor Pharmacology in Drug Discovery. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2010.161.issue-6.
© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20946109      PMCID: PMC3000656          DOI: 10.1111/j.1476-5381.2010.00931.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

Review 1.  Drug-target residence time and its implications for lead optimization.

Authors:  Robert A Copeland; David L Pompliano; Thomas D Meek
Journal:  Nat Rev Drug Discov       Date:  2006-08-04       Impact factor: 84.694

2.  Synthesis and evaluation of xanomeline analogs--probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor.

Authors:  Brian E Kane; Marianne K O Grant; Esam E El-Fakahany; David M Ferguson
Journal:  Bioorg Med Chem       Date:  2007-10-22       Impact factor: 3.641

Review 3.  Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation.

Authors:  Georges Vauquelin; Anna Szczuka
Journal:  Neurochem Int       Date:  2007-05-21       Impact factor: 3.921

Review 4.  Residence time of receptor-ligand complexes and its effect on biological function.

Authors:  Peter J Tummino; Robert A Copeland
Journal:  Biochemistry       Date:  2008-04-16       Impact factor: 3.162

5.  Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor.

Authors:  Carol Smith; Tariq Rahman; Nicole Toohey; Joseph Mazurkiewicz; Katharine Herrick-Davis; Milt Teitler
Journal:  Mol Pharmacol       Date:  2006-07-26       Impact factor: 4.436

6.  Guide to Receptors and Channels (GRAC), 4th Edition.

Authors: 
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

7.  Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.

Authors:  A Szczuka; M Wennerberg; A Packeu; G Vauquelin
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

8.  Antagonist-radioligand binding to D2L-receptors in intact cells.

Authors:  Ann Packeu; Jean-Paul De Backer; Isabelle Van Liefde; Patrick M L Vanderheyden; Georges Vauquelin
Journal:  Biochem Pharmacol       Date:  2008-03-14       Impact factor: 5.858

9.  A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.

Authors:  Susan Summerhill; Timothy Stroud; Roshini Nagendra; Christelle Perros-Huguet; Michael Trevethick
Journal:  J Pharmacol Toxicol Methods       Date:  2008-07-02       Impact factor: 1.950

10.  Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors.

Authors:  Siobhan Malany; Lisa M Hernandez; William F Smith; Paul D Crowe; Sam R J Hoare
Journal:  J Recept Signal Transduct Res       Date:  2009       Impact factor: 2.092

View more
  7 in total

Review 1.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

2.  Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling.

Authors:  Anna H C Vlot; Wilhelmus E A de Witte; Meindert Danhof; Piet H van der Graaf; Gerard J P van Westen; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

Review 3.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

4.  New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics.

Authors:  Markus Zeilinger; Florian Pichler; Lukas Nics; Wolfgang Wadsak; Helmut Spreitzer; Marcus Hacker; Markus Mitterhauser
Journal:  EJNMMI Res       Date:  2017-03-07       Impact factor: 3.138

5.  Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists.

Authors:  Lizi Xia; Henk de Vries; Eelke B Lenselink; Julien Louvel; Michael J Waring; Leifeng Cheng; Sara Pahlén; Maria J Petersson; Peter Schell; Roine I Olsson; Laura H Heitman; Robert J Sheppard; Adriaan P IJzerman
Journal:  J Med Chem       Date:  2017-11-21       Impact factor: 7.446

6.  A two-state model for the kinetics of competitive radioligand binding.

Authors:  Dong Guo; Lambertus A Peletier; Lloyd Bridge; Wesley Keur; Henk de Vries; Annelien Zweemer; Laura H Heitman; Adriaan P IJzerman
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

7.  Ligand with Two Modes of Interaction with the Dopamine D2 Receptor-An Induced-Fit Mechanism of Insurmountable Antagonism.

Authors:  Richard Ågren; Hugo Zeberg; Tomasz Maciej Stępniewski; R Benjamin Free; Sean W Reilly; Robert R Luedtke; Peter Århem; Francisco Ciruela; David R Sibley; Robert H Mach; Jana Selent; Johanna Nilsson; Kristoffer Sahlholm
Journal:  ACS Chem Neurosci       Date:  2020-09-15       Impact factor: 4.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.